Lilly's triple agonist retatrutide delivered powerful weight loss in pivotal Phase 3 obesity trial Eli Lilly and Company TRANSCEND-T2D-1 topline results Lilly reports positive topline results in adults with type 2 diabetes inadequately controlled on diet and exercise alone
We examine which peptides will be reviewed, the regulatory steps that follow the PCAC meeting, and what the outcome could mean for patient access and the broader future of personalized medicine
CV outcomes data (SELECT) These compounds are not interchangeable
Try the BMI Calculator Table of contents The phase 2 blood pressure data in detail How BP responds to weight loss generally Mechanisms beyond weight loss Comparison across the GLP-1 class What happens to antihypertensive medications during weight loss Orthostatic considerations The patient who improves dramatically vs the patient who does not When to monitor and how Cardiovascular outcome implications The contrary view: weight loss is not always durable FAQ Sources The phase 2 blood pressure data in detail The Jastreboff et al
Outer thighs present another accessible option, particularly the mid to upper outer region
This does not invalidate the findings, but it is a standard scientific quality consideration that most pages omit